Oligodendroglioma: Symptoms, Grades, Diagnosis and Treatment (2026 Guide)

Medically reviewed content · Published 2026 · Last reviewed August 2026

Oligodendroglioma is a diffuse glioma of the central nervous system that, under the current World Health Organization (WHO) classification, is defined molecularly not just by how it looks under the microscope. To be classified as oligodendroglioma today, a tumor must have both an IDH mutation and whole-arm 1p/19q codeletion; histology alone is no longer sufficient for the diagnosis. Oligodendrogliomas are graded as CNS WHO grade 2 or grade 3. This is one of the most important facts a newly diagnosed patient can understand: an IDH-mutant diffuse glioma that does not have 1p/19q codeletion is not oligodendroglioma — it’s classified as astrocytoma instead, a related but distinct tumor with different treatment considerations.

This guide explains what the molecular diagnosis actually means, how oligodendroglioma is graded and staged, current treatment approaches — including maximal safe surgery, radiation, PCV and temozolomide chemotherapy, and newer IDH-targeted therapy — and what treatment for this uncommon brain tumor looks like for international patients considering care in India. This is general medical education, not a diagnosis or an individual treatment recommendation.

Oligodendroglioma vs. Other Gliomas

Oligodendroglioma is not simply “a less aggressive glioblastoma” — it’s a distinct molecular entity that happens to generally behave less aggressively, but it is still a malignant, infiltrative tumor that requires active treatment and long-term monitoring, not a tumor to think of as harmless.

Understanding the Molecular Diagnosis

What does IDH-mutant mean?

IDH1 and IDH2 are genes that encode enzymes involved in normal cellular metabolism. Mutations in these genes are central to how modern diffuse gliomas are classified — IDH-mutant gliomas, as a broad category, are biologically distinct from IDH-wildtype gliomas (like most glioblastomas) and are generally associated with a more favorable prognosis. However, an IDH mutation alone does not establish a diagnosis of oligodendroglioma — it’s a necessary but not sufficient finding. Not all IDH mutations are identical either; IDH1 R132H is the most common specific alteration, but other IDH1 and IDH2 mutation variants exist and are tested for using a combination of immunohistochemistry and sequencing.

What is whole-arm 1p/19q codeletion?

Whole-arm 1p/19q codeletion is the second, equally required molecular feature. In plain terms: chromosomes come in pairs, and each chromosome has two “arms” (a shorter “p” arm and a longer “q” arm). In oligodendroglioma, tumor cells have lost an entire copy of the short arm of chromosome 1 (1p) together with an entire copy of the long arm of chromosome 19 (19q) — this combined, whole-arm loss pattern is what “codeletion” refers to. This specific finding is what distinguishes oligodendroglioma from astrocytoma at the molecular level, and it must be a whole-arm loss — a partial deletion of part of 1p or 19q doesn’t meet the diagnostic criteria, which is why accurate, appropriately validated molecular testing (typically FISH or a broader genomic panel) is essential rather than optional.

Other molecular findings

Oligodendrogliomas frequently also show additional molecular alterations involving the TERT promoter, and the genes CIC and FUBP1. These findings are commonly present and support the diagnosis, but they do not replace the requirement for IDH mutation plus whole-arm 1p/19q codeletion — they’re supportive, not defining, findings. CDKN2A/B deletion is another alteration that has emerging prognostic relevance in IDH-mutant gliomas generally, including some oligodendrogliomas, and is an active area of research into refining risk stratification within grade 2 and grade 3 disease — but as of 2026, consensus on exactly how to incorporate it into routine grading for oligodendroglioma specifically has not been fully established, so its role is best discussed directly with your neuropathology and neuro-oncology team rather than treated as a settled classification factor.

How Common Is Oligodendroglioma, and Who Gets It?

Oligodendroglioma is uncommon compared with many other brain tumors — it represents a minority of adult diffuse gliomas overall, most of which are the more common astrocytoma or glioblastoma categories. Most oligodendrogliomas are diagnosed in adults, commonly in middle adulthood, and the tumor is uncommon in children.

Precise incidence figures vary between registries and studies, partly because the 2021 WHO reclassification changed which tumors are counted as oligodendroglioma at all — a meaningful number of tumors that would have been called oligodendroglioma under older, histology-only criteria are now classified as astrocytoma once molecular testing is applied, which is worth knowing if you’re comparing older statistics to current ones.

Causes and Risk Factors

The exact cause of oligodendroglioma is generally unknown. It arises from genetic and molecular changes within tumor cells themselves — including the IDH mutation and 1p/19q codeletion discussed above — but what triggers these changes in a given individual is not established. There is no established lifestyle cause, and no evidence that ordinary daily activities or exposures directly cause this tumor. If you’re looking for something you did that caused this, the honest, current answer is that there generally isn’t one to find.

Symptoms of Oligodendroglioma

Symptoms depend on tumor location, size, growth rate, pressure effects on nearby brain structures, and whether the tumor is triggering seizure activity. Common symptoms include:

• Seizures
• Headaches
• Memory problems
• Changes in concentration
• Personality or behavior changes
• Weakness
• Numbness
• Speech or language difficulties
• Vision changes
• Balance problems

Seizures are a particularly common presenting feature of oligodendroglioma and other lower-grade diffuse gliomas — often the very first symptom that leads to the brain imaging that finds the tumor. This happens because tumors located in or near the brain’s outer layer (cortex) can irritate surrounding, otherwise normal brain tissue, producing abnormal electrical activity. It’s worth being clear, though, that a seizure does not mean a brain tumor is present — seizures have many causes, and most first-time seizures in the general population are not due to a brain tumor.

Symptoms by brain location

Symptoms vary substantially by location — two tumors of similar size in different parts of the brain can produce very different symptom patterns.

When to seek urgent care

Urgent medical assessment is warranted for a first-ever seizure, a prolonged seizure, repeated seizures without recovery in between, sudden severe weakness, sudden speech difficulty, sudden loss of consciousness, or a severe, rapidly worsening headache accompanied by neurologic symptoms. These situations require emergency medical evaluation, not a routine appointment.

How Oligodendroglioma Is Diagnosed

1. Clinical evaluation and neurologic examination
2. MRI
3. Surgical biopsy or tumor resection
4. Histopathology
5. Molecular testing (IDH and 1p/19q status)
6. WHO classification and grade assignment
7. Multidisciplinary treatment planning

MRI and imaging

MRI is the primary imaging modality for a suspected diffuse glioma, using a combination of sequences — T1-weighted, T2-weighted, FLAIR, contrast-enhanced imaging, and sometimes diffusion or perfusion/spectroscopy sequences in selected situations — to characterize the tumor’s location, size, and relationship to surrounding structures. Calcification within the tumor is a feature historically associated with oligodendroglioma and can sometimes be seen on MRI or more sensitively on CT, but calcification does not prove the diagnosis — it’s a supportive imaging clue at most. Imaging can strongly suggest a diffuse glioma is present, but it cannot replace tissue diagnosis; the current molecular diagnosis of oligodendroglioma can only be made through biopsy or surgical tissue.

Biopsy and surgery

Tissue is required for definitive classification. Depending on the tumor’s location and the clinical situation, this may come from a stereotactic biopsy (a smaller, targeted sampling procedure) or from surgical resection performed with the dual goal of establishing the diagnosis and removing as much tumor as safely possible. Surgery, when appropriate, provides tissue for diagnosis and molecular classification, reduces tumor burden, and can relieve pressure-related symptoms in selected cases.

Pathology and molecular testing

Molecular testing is essential, not optional, for a modern oligodendroglioma diagnosis. Pathology combines histologic examination with IDH mutation testing (typically immunohistochemistry for the common IDH1 R132H mutation, with sequencing used when initial testing is negative but suspicion remains) and 1p/19q codeletion testing (typically fluorescence in situ hybridization, FISH, or a broader next-generation sequencing panel that can detect whole-arm chromosomal changes). A diagnosis of oligodendroglioma based on how the cells look under the microscope alone, without this molecular confirmation, does not reflect current diagnostic standards.

Oligodendroglioma Grades: 2 vs. 3

Under current classification, oligodendroglioma is graded as CNS WHO grade 2 or CNS WHO grade 3 — there is no grade 1 oligodendroglioma, and there is no grade 4 oligodendroglioma (a grade 4 IDH-mutant, 1p/19q-codeleted tumor would not fit the current classification framework).

Grade 2 does not mean benign — it is still a malignant, infiltrative tumor that requires ongoing specialist management. Grade 3 does not mean automatically incurable or untreatable — recent research applying current molecular criteria has actually found that once tumors are correctly classified using IDH mutation and 1p/19q codeletion, the survival difference between grade 2 and grade 3 oligodendroglioma narrows considerably compared to older, histology-only-classified cohorts — underscoring that the molecular diagnosis itself carries more prognostic weight than grade alone. It is one important input into treatment planning and prognosis, not the entire picture.

Oligodendroglioma Treatment Overview

Treatment depends on age, neurologic function, tumor location, tumor size, extent of surgical resection achieved, CNS WHO grade, molecular profile, presence of residual tumor, symptoms, prior treatment, and patient preferences. Available approaches include maximal safe surgery, observation in carefully selected patients, radiation therapy, chemotherapy (PCV or temozolomide), newer IDH-targeted therapy in specific situations, clinical trials, and supportive care. There is no single universal treatment pathway — a multidisciplinary neuro-oncology team weighs these factors together for each patient.

Maximal safe surgery

The general surgical goal is maximal safe removal of tumor while preserving important neurologic function — not necessarily complete removal at any cost. The achievable extent of resection depends on tumor location, whether it involves “eloquent” brain regions (areas controlling movement, language, or other critical functions), tumor size, its relationship to major blood vessels, the use of intraoperative functional mapping, and the patient’s overall health. Complete removal is not always possible or, in some cases involving strong involvement of critical structures, always the right goal if it would come at the cost of significant, avoidable neurologic injury.

Awake brain surgery (awake craniotomy with functional mapping) may be used for tumors near important language or motor areas — the patient is kept awake and responsive during key parts of the procedure so the surgical team can directly test brain function in real time and maximize safe tumor removal while protecting critical abilities like speech or movement. Not every patient needs this approach; it’s specifically considered when a tumor’s location puts eloquent brain regions at meaningful risk.

Observation and active surveillance

For selected patients — generally those with favorable features after extensive resection and no concerning clinical symptoms — active monitoring rather than immediate radiation or chemotherapy may be considered. Factors influencing this decision include age, extent of resection achieved, tumor size, presence of symptoms, grade, amount of residual disease, and molecular profile. This is a genuinely individualized decision made with a specialist, not a default path for every grade 2 tumor, and not every patient with residual disease after surgery is a safe candidate for observation.

Radiation therapy

Radiation may be used after surgery for higher-risk disease, for grade 3 tumors, for residual or recurrent disease, and in selected grade 2 cases where risk factors warrant it. Modern techniques include intensity-modulated radiation therapy (IMRT), image-guided radiation delivery, and, where clinically appropriate and available, proton therapy. Radiation is frequently combined with chemotherapy rather than used alone in higher-risk disease, based on evidence discussed below.

Chemotherapy: PCV and temozolomide

PCV (procarbazine, lomustine/CCNU, and vincristine, given together as a combination regimen) has an established, long-term evidence base in oligodendroglioma when combined with radiation — long-term follow-up from pivotal trials (RTOG 9402 and EORTC 26951) demonstrated a durable overall survival benefit specifically in 1p/19q-codeleted tumors when PCV was added to radiation, a finding that helped establish the current molecular-first treatment approach. Temozolomide is an oral chemotherapy drug widely used across glioma treatment generally and may be used in oligodendroglioma in selected situations, particularly when toxicity concerns make PCV less suitable — a 2025 clinical guideline update specifically notes that radiation plus temozolomide can be offered as an alternative to radiation plus PCV when toxicity is a concern.

Neither drug is universally superior — the specific choice depends on current guidelines, the individual patient’s ability to tolerate each regimen’s specific toxicity profile, and treatment goals, and should be made with your treating neuro-oncologist rather than assumed from general information.

Newer treatment developments: IDH-targeted therapy

Vorasidenib, an oral, brain-penetrating inhibitor of mutant IDH1/2 enzymes, represents a genuinely new development in this field. Based on the positive Phase III INDIGO trial, it has received regulatory approval specifically for IDH-mutant grade 2 glioma (including oligodendroglioma) following surgery, in situations where the patient and treating team have decided that radiation and chemotherapy can reasonably be deferred. Current 2025 clinical guidance specifically notes vorasidenib can be offered for grade 2 IDH-mutant oligodendroglioma after at least one surgery, when further radiation or chemotherapy has been, or can be, deferred.

Its use in grade 3 disease is less established — this remains an active area of clinical research, with case reports and ongoing studies exploring its role outside the grade 2, post-surgery, treatment-deferred setting where it’s currently approved. This is a genuinely fast-evolving area of oligodendroglioma treatment; whether and how it applies to an individual case should be confirmed directly with a treating neuro-oncologist familiar with current, specific approval criteria, not assumed from general awareness that the drug exists.

Recurrent Disease and Progression

Recurrence can occur after surgery, radiation, or chemotherapy, and treatment for recurrence depends on prior therapy received, the location of the recurrence, time elapsed since initial treatment, current molecular profile, and neurologic function. Options may include repeat surgery, radiation or re-irradiation in selected cases, further chemotherapy, IDH-targeted therapy where appropriate to the specific clinical situation, or clinical trial participation.

Oligodendroglioma can also become biologically more aggressive over time — a process sometimes called progression or malignant transformation, where a tumor initially graded as grade 2 develops higher-grade histologic features on subsequent biopsy or resection. This is a recognized possibility, not an inevitability, and its likelihood and timeline vary considerably between patients.

Prognosis and Survival

Prognosis depends on CNS WHO grade, age, functional status, tumor location, extent of surgical resection, amount of residual disease, molecular characteristics, treatment response, and whether or when recurrence occurs. IDH mutation and whole-arm 1p/19q codeletion together define a tumor biology that is generally associated with more favorable outcomes compared with many other diffuse gliomas, including IDH-mutant astrocytoma and especially IDH-wildtype glioblastoma.

Recent research applying current molecular classification criteria found median overall survival in the range of 12–13 years for correctly molecularly classified oligodendroglioma — notably, with the gap between grade 2 and grade 3 disease narrowing considerably once molecular criteria (rather than histology alone) were used to define the cohort, compared to tumors that were histologically labeled oligodendroglioma but didn’t actually meet the molecular criteria, which showed meaningfully shorter survival in the same analysis. These figures come from a specific study population and treatment era, and — as with any survival statistic — should not be read as a prediction for any individual patient; your own prognosis depends on your specific grade, molecular profile, extent of resection, treatment response, and overall health, best discussed directly with your treating neuro-oncology team rather than estimated from a published study population.

Long-Term Follow-Up and Quality of Life

Because oligodendroglioma can recur years after initial treatment, long-term — often effectively lifelong — surveillance is standard, generally including periodic neurologic assessment, follow-up MRI, functional assessment, and monitoring for any treatment-related toxicity over time. Your specialist team will set a specific surveillance schedule tailored to your grade, molecular profile, and treatment history — there’s no single universal MRI interval that applies to every patient.

Quality of life considerations can include the ongoing management of seizures, cognitive changes, fatigue, speech or language difficulties, motor deficits, and the after-effects of radiation or chemotherapy, alongside emotional health throughout what is often a long-term relationship with a neuro-oncology team rather than a single course of treatment with a defined endpoint. Rehabilitation services — including cognitive rehabilitation, physical therapy, and speech therapy where relevant — are an appropriate and often valuable part of supportive care alongside oncologic treatment.

Oligodendroglioma Treatment Cost in India

There is no single “oligodendroglioma treatment cost” — total cost depends on extent of surgery required, whether radiation and/or chemotherapy follow, and how molecular testing and any follow-up treatment factor in. Below is a component breakdown based on currently published figures for comparable brain tumor care in India, which vary by hospital and city.

Why International Patients Consider India for Oligodendroglioma Care, and How to Choose a Center

India has developed substantial neuro-oncology and neurosurgical capacity, including access to advanced MRI, functional brain mapping, modern radiation techniques, and molecular pathology — for international patients, the appeal is typically this combination with costs generally lower than the US, UK, or much of Europe. India isn’t automatically “the best” choice for every patient, however; several countries also offer strong neuro-oncology programs, and the right choice depends on an individual patient’s specific tumor, budget, and travel considerations.

When evaluating a center for oligodendroglioma care in India or anywhere look for:

• A dedicated neuro-oncologist and neurosurgeon with brain tumor-specific experience, not general oncology or general neurosurgery alone
• A neuropathologist and molecular pathologist capable of confirming IDH status and 1p/19q codeletion in-house or with a reliable, validated external lab
• Advanced MRI and, where relevant, intraoperative functional mapping capability for awake surgery
• Modern radiation oncology, including access to IMRT and, if clinically appropriate, proton therapy
• Access to current chemotherapy regimens (PCV and temozolomide) and awareness of newer IDH-targeted therapy where relevant
• ICU-level supportive care and rehabilitation services
• A genuine multidisciplinary neuro-oncology tumor board
• Clinical trial access, where relevant to your specific situation
• Established international patient services (visa letters, coordination, interpreter support)

Ask directly about the center’s specific experience with molecularly confirmed oligodendroglioma, not just general brain tumor volume, and verify credentials independently rather than relying on third-party “top hospital” rankings.

The International Patient Treatment Journey

1. Share existing MRI and medical reports for review
2. Provide pathology slides or tissue blocks, if a prior biopsy or surgery has already occurred
3. Confirm histologic and molecular diagnosis — specifically IDH status and whole-arm 1p/19q codeletion
4. Determine CNS WHO grade
5. Review extent of resection, if surgery has already occurred
6. Multidisciplinary neuro-oncology specialist opinion
7. Treatment plan developed, with alternatives explained
8. Hospital and specialist confirmation
9. Written, itemized cost estimate
10. Medical visa guidance
11. Travel and accommodation arrangements
12. Treatment delivery
13. Follow-up MRI and long-term monitoring planning
14. Remote follow-up and report-sharing with the home-country physician

No credible provider can guarantee a diagnosis, surgical eligibility, complete tumor resection, cure, treatment response, an exact final cost, visa approval, or survival outcome before reviewing a patient’s actual imaging and pathology — be cautious of any provider offering these guarantees upfront.

Questions to Ask Your Neuro-Oncology Team

• Is my tumor confirmed as IDH-mutant, and is whole-arm 1p/19q codeletion confirmed?
• Has the pathology been reviewed by an experienced neuropathologist?
• What is my CNS WHO grade?
• How much of the tumor was removed, and is there residual disease?
• Is further surgery appropriate, now or in the future?
• Is radiation recommended, and would PCV or temozolomide be used alongside it, and why?
• Is observation reasonable in my specific situation instead of immediate radiation or chemotherapy?
• Would IDH-targeted therapy (such as vorasidenib) be appropriate for my case?
• Are there relevant clinical trials I should know about?
• What is my recurrence risk, and how will it be monitored?
• How often will follow-up MRI be performed, and for how long?
• What symptoms should prompt me to seek urgent care?
• What rehabilitation or supportive care might I need?

How Shifam Health Helps International Oligodendroglioma Patients

Shifam Health is a medical tourism facilitator, not a cancer hospital, neurosurgery center, or pathology laboratory — we don’t diagnose oligodendroglioma or determine treatment plans. What we do is help international patients navigate the practical side of accessing oligodendroglioma care in India: coordinating the review of imaging and pathology by relevant specialists, helping identify hospitals with genuine neuro-oncology and molecular pathology capability, obtaining written treatment and cost estimates, assisting with medical visa documentation, arranging airport pickup and accommodation, providing interpreter support where needed, and staying in touch for follow-up communication once you return home.

If you or someone you’re caring for has received this diagnosis, share your available reports with our team on WhatsApp or through a quick inquiry form — there’s no obligation, and we typically respond within 24 hours.

Frequently Asked Questions

Conclusion

Oligodendroglioma is, first and foremost, a molecularly defined tumor — IDH mutation and whole-arm 1p/19q codeletion together, not histology alone, are what confirm the diagnosis and distinguish it from the related but different astrocytoma. Understanding this distinction, confirming your specific CNS WHO grade, and working with a genuinely experienced neuro-oncology team are the most useful steps a newly diagnosed patient or caregiver can take — both to understand what the diagnosis actually means and to make an informed decision about treatment, in India or anywhere else.

This article is for general medical education and does not replace individualized advice from a qualified neuro-oncologist, neurosurgeon, or radiation oncologist. It is not a diagnosis, treatment recommendation, or guarantee of any outcome.